Figure 1: Map of biosimilar adoption across southern & northern provinces in Italy
Figure 2: Map of biosimilar adoption across eastern & western provinces in Germany
Figure 3: Association between biosimilar adoption & gov. trust in Italy & Germany

GERMANY And ITALY – Anti-TNF and Oncology Biosimilars

*Weighted average of 2021 YTD Bs market share for Humira, Embrel, Remicade, Herceptin, Avastin, and Rituxan biosimilars. Weighted by sales.
Figure 4: Association bet. biosimilar adoption & regional GDP / capita in Italy & Germany

*Weighted average of 2021 YTD Bs market share for Humira, Embrel, Remicade, Herceptin, Avastin, and Rituxan biosimilars. Weighted by sales.
Figure 5: Map of biosimilar adoption across European nations

Europe Biosimilar Market Penetration
Weighted Avg. Onc. & TNF Bs vs Referenced Product

Country Bs market share data not provided
Coloring determined by whether market share was above or below basket median
Figure 6: Association between biosimilar adoption & gov. trust in European nations

Europe Biosimilar Market Penetration by EQI
*Weighted Avg. Onc. & TNF Bs by national EQI*

The following nations did not have EQI data listed or are not included on this graph: RO, CH.
Figure 7: Association bet. biosimilar adoption & GPD per capita in European nations

Europe Biosimilar Market Penetration by GDP Per Capita

Weighted Avg. Onc. & TNF Bs by national GDP Per Capita